Treatment of Chronic HCV With Sofosbuvir (SOF) and Simeprevir (SMV) in Patients With Cirrhosis and Contraindications to Peginterferon (PEGINF) and Ribavirin (RBV)

Shiffman Mitchell; James Amy; Long April; Alexander Philip

首页> 外文期刊>The American Journal of Gastroenterology >Treatment of Chronic HCV With Sofosbuvir (SOF) and Simeprevir (SMV) in Patients With Cirrhosis and Contraindications to Peginterferon (PEGINF) and Ribavirin (RBV)

【24h】

Treatment of Chronic HCV With Sofosbuvir (SOF) and Simeprevir (SMV) in Patients With Cirrhosis and Contraindications to Peginterferon (PEGINF) and Ribavirin (RBV)

机译：索非布韦（SOF）和西美普韦（SMV）在肝硬化和聚乙二醇干扰素（PEGINF）和利巴韦林（RBV）的禁忌症患者中治疗慢性HCV

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《The American Journal of Gastroenterology》 |2014年第2期|共2页
作者
Shiffman Mitchell; James Amy; Long April; Alexander Philip;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Treatment of Chronic HCV With Sofosbuvir (SOF) and Simeprevir (SMV) in Patients With Cirrhosis and Contraindications to Peginterferon (PEGINF) and Ribavirin (RBV) [J] . Shiffman Mitchell, James Amy, Long April, The American Journal of Gastroenterology . 2014,第Suppla2期

机译：索非布韦（SOF）和西美普韦（SMV）在肝硬化和聚乙二醇干扰素（PEGINF）和利巴韦林（RBV）的禁忌症患者中治疗慢性HCV
2. All-Oral Treatment With Daclatasvir (DCV) Plus Sofosbuvir (SOF) Plus Ribavirin (RBV) for 12 or 16 Weeks in HCV Genotype (GT) 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+Phase 3 Study [J] . Leroy Vincent, Angus Peter W., Bronowicki Jean-Pierre, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2015,第6期

机译：HCV基因型（GT）3感染的患有晚期纤维化或肝硬化的患者，用达卡他韦（DCV）加索非布韦（SOF）加利巴韦林（RBV）全口服治疗12或16周：ALLY-3 + Phase 3研究
3. French Hepatitis C (HCV) Patients Treated with Anti-viral Combinations Containing Pegylated Interferon (IFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV), Velpatasvir (VEL) and/or Voxilaprevir (VOX): The Impact of Treatment on Patient-Reported Outcomes (PROs) [J] . Cacoub Patrice P., Bourliere Marc, Asselah Tarik, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：法国丙型肝炎（HCV）含有聚乙二醇干扰素（IFN），利巴韦林（RBV），Sofosbuvir（SOF），LEDIPASVIR（LDV），VELPATASVIR（VEL）和/或VoxILAPREVIR（VOX）的抗病毒组合患者：影响对患者报告的结果（专业）的治疗
4. Safety of Peginterferon alfa-2a (PEGASYS) 180 mcg Weekly Plus Ribavirin (RBV) 800 mg Daily in HIV/HCV Coinfection Compared to HCV Monoinfection [C] . N. Brau, F.J. Torriani, M. Rodriguez Torres International AIDS Conference . 2004

机译：Peginterferon Alfa-2a（Pegasys）的安全性为180 mcg每周加上利韦韦林（RBV）800mg在HIV / HCV辛纤维中每日800毫克，与HCV单键相比
5. A168 USE OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) WITH OR WITHOUT RIBAVIRIN (RBV) IN GENOTYPE 1 (GT 1) HCV-INFECTED PATIENTS POST LIVER TRANSPLANT (LT): EVALUATION OF SEVERAL REAL-WORLD DATASETS (RWD) [O] . M Bourliere, M Charlton, M Manns, 2018

机译：A168在肝移植后（LT）的基因型1（GT 1）HCV感染患者中使用带或不带利巴韦林（RBV）的LEDIPASVIR / SOFOSBUVIR（LDV / SOF）：评估多个真实世界数据集（RWD）
6. Comparative Study between Triple Therapy (Peginterferon /Ribavirin/Sofosbuvir) and Dual Therapy (Simeprevir /Sofosbuvir) in Treatment of Chronic HCV Patients [O] . Adel Awaad, No’omaan El Garem, Tamer ELeraky, 2017

机译：三重疗法（Peginterferon / Ribavirin / Sofosbuvir）与双治疗（Simeprevir / Sofosbuvir）治疗慢性HCV患者的比较研究

Treatment of Chronic HCV With Sofosbuvir (SOF) and Simeprevir (SMV) in Patients With Cirrhosis and Contraindications to Peginterferon (PEGINF) and Ribavirin (RBV)

著录项

引文网络

相似文献

相关主题

期刊订阅